Bioventus Inc. (BVS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 31/100 (MEDIUM), 25.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 9.4% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Bioventus (BVS) Q2 2026 Earnings Call Transcript
- Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings
- The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance
- Is Bioventus (BVS) Stock Undervalued Right Now?
- Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year?
- Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?
- Bioventus (BVS) Stock Looks Overvalued On Earnings Yet Backed By Broader Checks
- Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Bioventus Inc..
Full BVS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.